Back to Search
Start Over
Additional file 1: Table S1. of Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- Publication Year :
- 2016
- Publisher :
- Figshare, 2016.
-
Abstract
- Dose adjustment and toxicity management guidelines—non-hematologic toxicities. Table S2 Serious adverse events and deathsa occurring in phase 1 component of the study (n = 43). Table S3 Day 1 pharmacokinetics of pacritinib in the phase 1 part of the study (n = 43). Table S4 Day 15 pharmacokinetics of pacritinib in the phase 1 part of the study (n = 43). Table S5 Percent change from baseline at week 24 for individual and total symptom scores from the Myelofibrosis Quality of Life and Symptom Assessment Tool—phase 2 (efficacy evaluable population). Table S6 Median percent change from baseline in hematologic parameters over time in the phase 2 component of the study (n = 31). Table S7 Serious adverse events and deathsa occurring in the phase 2 component of the study (n = 31). Figure S1 Mean concentration-time profiles of pacritinib when dosed as hydrochloride and citrate salts at a dose of 200 mg. (DOC 296 kb)
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi...........dcf917a082ffc7f4652eb6c01df338a1
- Full Text :
- https://doi.org/10.6084/m9.figshare.c.3599231_d1.v1